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1. INTRODUCTION 
 
 
Tuberculosis (TB) is a disease that has severely affected communities and 
nations since times immemorial. The disease has brought untold miseries to 
generations and even today, when newer modalities for diagnosis and treatment 
of TB have made the disease curable, people are suffering and dying from the 
disease.1 
 
Tuberculosis remains the number one killer infectious disease affecting adults in 
developing countries. The 1990 World Health Organization (WHO) report on the 
Global Burden of Disease ranked TB as the seventh most morbidity-causing 
disease in the world, and expected it to continue in the same position up to 20202 
 
During 2004, it was estimated that about nine million new cases of TB occurred 
globally. India contributes a fifth of these cases, i.e., about 1.8 million, of which 
0.8 million are new sputum-positive infectious cases. Nearly 400,000 estimated 
deaths occur annually due to tuberculosis. 75% of the people with tuberculosis 
are in the economically productive age group.3 
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The global community woke up to this disease when, in 1993, the WHO declared 
TB as a global emergency.1 
 
The control of tuberculosis requires tremendous technical and managerial inputs. 
Tuberculosis control strategies have implemented a variety of operational 
elements through the history of its evolution. New approaches were introduced, 
as a result of a pressing need, a new discovery or a breakthrough in research. 
The current Directly Observed Treatment Short-course (DOTS) strategy is one 
such approach. 
 
The DOTS strategy has shown encouraging results in areas where it has been 
implemented. It is based on a managerial approach to TB control with sound 
technical foundations. Its five core elements include sustained political 
commitment, short-course chemotherapy administered under proper case-
management conditions, diagnosis primarily by sputum smear microscopy, 
regular drug supply and a sound monitoring system.4  
 
The DOTS strategy for TB control recommended by the World Health  
Organization (WHO) is hailed as one of the most cost-effective of all health 
interventions to date.5 
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Under the DOTS Program patients are classified into 3 treatment categories—
Categories I, II and III depending on the indication and previous history of 
treatment.   
Category I is for New sputum smear-positive or Seriously ill sputum smear-
negative or Seriously ill extra-pulmonary, treatment is with 2 Months of  Isoniazid 
(H), Rifampicin(R), Pyrazinamide(Z) and Ethambutol(E) thrice a week, directly 
supervised followed by 4 months of isoniazid and rifampicin 
(2H3R3Z3E3+4H3R3) 
 
Category II involves patients undergoing retreatment due to relapse, failure, 
default or others.  
Cat II is treatment for a total duration of 8 months with 3 months of intensive 
phase comprising of  2 H3R3Z3E3S3 and 1 H3R3Z3E3 followed by 5 months of 
continuation phase with 5 H3R3E3.(S= streptomycin) 
Category III constitutes  New sputum smear-negative, not seriously ill New extra-
pulmonary, not seriously ill -2H3R3Z3+4H3R3 
 
While many studies have been performed evaluating the efficacy of Category I 
treatment, not much is known about the effectiveness of anti-tubercular treatment 
for patients in Category II treatment.   
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2. BACKGROUND 
 
Tuberculosis remains a major public health problem in India.  
From January 2001 onwards, the externally funded Revised National 
Tuberculosis Control Programme (RNTCP) with its DOTS strategy officially 
began in Vellore district of Tamil Nadu. 
 
Community health and development (CHAD) hospital run by the department of 
Community Medicine, Christian Medical College and Hospital (CMCH) Vellore, is 
functioning as a tuberculosis unit (TU) under the RNTCP.  Vellore town patients 
are covered by the TB unit under Vellore District tuberculosis centre. There is an 
DOTS Clinic functioning in CMC hospital  getting patients from all the 
departments of CMC.  Annually around 600 patients will be started on 
Antitubercular Treatment (ATT) through the DOTS clinics and peripheral health 
systems. Cat II treatment constitutes about   10 – 15% of these cases. 
 
One of the challenges in tuberculosis is treating patients who have failed initial 
attempts to cure their disease.  These patients are moved into Category II in an 
attempt to provide further intervention. 
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The principal barrier to the elimination of tuberculosis is non-compliance with 
therapy by patients. The WHO has accordingly stressed the need for direct 
observation of therapy, which, as implied by the name, is the central feature of 
the widely advocated directly observed therapy short-course (DOTS) strategy6 
 
While many studies have been performed evaluating the efficacy of Category I 
treatment, not much is known about the effectiveness of anti-tubercular treatment 
for patients in Category II treatment under the programme conditions.   
 
The overall favourable re-treatment outcome in the Bangalore cohort was 39.8% 
as a result of a high proportion of ‘defaults’ (43.8%). However, favourable 
outcome among those completing the prescribed duration of treatment was75%, 
irrespective of pre-treatment drug susceptibility status. 8.  
 
It is, however, now evident that non-compliance is not the fault of the patient but 
due to gross inadequacies in the provision of health care7 
 
The argument against Cat II regimen for re-treatment cases by many physicians 
is the fear of adding a single drug to a failing regimen, causing emergence of 
further drug resistance, particularly MultiDrugResistence (MDR). 
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Does Category II treatment address the need to control refractory cases and 
non-adherent patients?  Indeed, it is important to evaluate whether or not current 
attempts to control difficult tuberculosis cases with Category II  treatment is 
effective.  
 
Knowledge regarding risk factors for poor outcome will show areas of focus 
needed to increase effectiveness of Cat II treatment. 
 
The present study is an attempt to address few of  the above questions. 
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3. OBJECTIVES 
 
 
 
1) To study the profile of tuberculosis patients on Category II 
treatment in a population covered by CHAD/ C M C H DOTS clinic 
under RNTCP . 
 
2) To study outcome of treatment in the same patients after a time of 
followup as compared to the immediate outcome after treatment. 
 
3) To study the risk factors associated with poor outcomes in the 
above group of patients 
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4. REVIEW OF LITERATURE 
4.1 TUBERCULOSIS – AN OVERVIEW 
TB is a worldwide pandemic; though the highest rates per capita are in Africa 
(29% of all TB cases), half of all new cases are in 6 Asian countries (Bangladesh, 
China, India, Indonesia, Pakistan, the Philippines). 
2 billion people, equal to one-third of the world’s total population, are infected 
with TB bacilli, the microbes that cause TB.9 
TB is contagious and spreads through droplet infection; if not treated, each 
person with active TB infects on average 10 to 15 people every year. 
According to WHO, TB infection is currently spreading at the rate of one person 
per second. It kills more young people and adults than any other infectious 
disease and is the world's biggest killer of women. In 1993, WHO declared TB to 
be "a global health emergency". Every year 8–10 million people catch the 
disease and 2 million die from it. Around 10% of people infected with TB actually 
develop the disease in their lifetimes, but this proportion is changing with HIV 
coinfections as HIV severely weakens the human immune system and makes 
people much more vulnerable. 
In 2004, estimated per capita TB incidence was stable or falling in five out of six 
WHO regions, but growing at 0.6% per year globally. The exception is the African 
region, where TB incidence was still rising, in line with the spread of HIV. 
However, the number of cases notified from the African region is increasing more 
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slowly each year, probably because the HIV epidemics in African countries are 
also slowing. In eastern Europe (mostly countries of the former Soviet Union), 
incidence per capita increased during the 1990s, and peaked around 2001, but 
has since fallen. 
In 2005, 46 African Health Ministers declared TB a regional emergency in 
Africa; the Regional Director for WHO’s European Region also warned of a 
TB emergency in Europe. 
 
The 2006 WHO report Global TB Control concluded that three (of six) WHO 
regions are likely to have met both the 2005 targets: the Region of the Americas 
and the South-East Asia and Western Pacific regions. Seven of the 22 high-
burden countries are likely to have met the 2005 targets: Cambodia, China, India, 
Indonesia, Myanmar, the Philippines and Viet Nam within the 2005 timeframe, 
though final confirmation will come at the end of 2006. 
 
India has the largest number of tuberculosis cases in the world.4 Estimated 
prevalence of infection is 44% and of the disease is 505 per 1 00 000 population. 
Estimated incidence of pulmonary tuberculosis is about 187 per 1 00 000 and 
that of sputum smear for Acid Fast Bacilli positives is 84 per 1 00 000 in India.10 
Tuberculosis hinders the socioeconomic development of the country. 75% of 
people with tuberculosis are in the economically productive age group of 15–54 
years. Besides the disease burden, TB also causes an enormous socio-
economic burden on India. TRC, Chennai, undertook a study to estimate the 
socio-economic impact of tuberculosis in the country, from which it was 
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estimated that tuberculosis costs India more than $300 million annually in direct 
costs alone. Of this total, more than $100 million is incurred in the form of debt by 
patients and their families; and more than 100 million productive workdays are 
lost annually on account of tuberculosis 
TRC has documented the economic impact (out-of-pocket expenses) of TB on 
patients and their families. Even though diagnosis and treatment are offered free 
of cost to patients, the average total cost was Rs 5,986 per patient amounting to 
about Rs 13,000 crores a year for the country11. More than 3,00,000 children 
may have left school permanently because of their parents’ tuberculosis and 20 
percent had to take up jobs in order to supplement the household income, 
especially if the father had TB., and more than 1,00,000 women were rejected by 
their families because of having tuberculosis,12 thus TB, has the potential to 
impede the development of both individuals and society as a whole. 
 Review of studies investigating the economic impact of tuberculosis showed 
that, on an average, 3–4 months of work time are lost if an adult has 
tuberculosis, resulting in the loss of 20–30% of annual household income, and an 
average of 15 years of income is lost if the patient dies from the disease3 
By and large, prevalence figures are not quoted in most Indian references due 
mainly to the lack of consensus on data about the duration of the disease in the 
absence of any interventions. A recent study by the Tuberculosis Research 
Centre (TRC), Chennai, gives the average duration of the disease as three-and-
a-half years.13 However, the sample taken may not be sufficient to extrapolate to 
the whole of India.  
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4.2 THE HISTORY OF TUBERCULOSIS CONTROL 
 
4.2.1 EVOLUTION OF WHO TUBERCULOSIS CONTROL POLICIES 
 
The policies of the WHO went through various stages as experience was gained 
from therapeutic trials to field operations in different countries. 14,15  
 
Vertical programs that were successful in developed countries between 1948 and 
1963 were found unsuitable for poorer nations due to lack of resources.16 
Integration of tuberculosis control services into the general health services was 
then tried with equally unimpressive results.17,18 
 
Managerial integration and health sector reform came in the 1980s, which further 
pushed for decentralisation. This, however, led to the further weakening of the 
TB control structure as the TB experts were side-lined and policies were dumped 
on an unprepared peripheral health setup.19 
 
This dismal state of affairs in TB control, fuelled by the HIV epidemic and socio-
economic and political turmoil, led to its increased incidence in both developed 
and developing nations.20,21 With this alarming state of affairs, the WHO defined 
a new control strategy in 1991.22 WHO embarked on the promotion of an 
approach that was successfully implemented by K. Styblo of the IUATLD in some 
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of the poorest African countries, like Tanzania and Malawi. It set global targets 
for tuberculosis control of 85% cure and 70% case detection. In 1995, this 
framework was packaged and promoted aggressively under the brand name 
Directly Observed Treatment Short-course, or “DOTS”.23 
 
A variety of interventions have been evolved over the years to increase the 
compliance of patients to anti-tuberculosis treatment. The major inputs have 
been: 
• Domiciliary treatment - 1956 
• Supervised swallowing of drugs, also know as Directly Observed Treatment 
(DOT) - 1958 
• Intermittent dosing of drugs – 1961 to 1977 
• Short Course Chemotherapy (SCC) – 1972 to 1976 
• Direct Observation of Treatment Short course (DOTS) strategy – 199124 
 
4.2.2  INDIA - NATIONAL TUBERCULOSIS PROGRAMME 1962 
 
 
 National Tuberculosis Institute (NTI) was established in 1959 to evolve through 
research a practicable TB programme that could be applied in all parts of the 
country. The National tuberculosis programme (NTP) which was started in 1962 
created an extensive infrastructure for tuberculosis control and has succeeded in 
placing more than 13 lakh patients on treatment on a yearly basis. Based on the 
findings of the operational studies conducted, a draft recommendation for the 
District Tuberculosis Programme (DTP) was prepared in 1961, keeping in mind 
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an average Indian district, its population and health facilities available. Anantapur 
district in Andra Pradesh was chosen to establish the first model district TB 
centre (DTC). 
  
The National Tuberculosis Programme (NTP) policy as enunciated in the 
introduction manual of DTP comprised:  
• Domiciliary treatment  
• Use of a standard drug regimen of 12-18 months duration  
• Treatment free of cost  
• Priority to newly diagnosed patients, over previously treated patients  
• Treatment organization fully decentralized  
• Efficient defaulter system/mostly self-administered regimen  
• Timely follow up  
• Chemoprophylaxis not recommended as it is impractical on mass basis.  
 
NTP was a decentralized programme with District TB Centres (DTC) established 
for implementation of the programme at the district level. Below the level of 
district, it is integrated into the general health services provision through the 
network of Primary Health Centres and first and second level referral health 
institutes. The major objectives of the NTP were to diagnose as large a number 
of cases as possible and provide efficient treatment placing priority on smear 
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positive patients; and to implement those activities in an integral part of general 
health services. 
 
Under the NTP, the TB symptomatics have been by and large referred to the 
District Tuberculosis Centers (DTC) located at District head quarters for 
diagnosis. The patients who were diagnosed TB were referred back to the 
nearest Primary Health Centre from where the patients collected their drugs once 
a month for self administration at home. The patients returned to the DTC for the 
follow up check ups or for the treatment of side effects. 
 
In 1992 the Indian government undertook a joint review of the tuberculosis 
situation with the help of the WHO and the Swedish International Development 
Agency (SIDA). Based on these recommendations, the government of India 
came up with the Revised National Tuberculosis Control Program (RNTCP) in 
1993 which is the Indian version of the ‘DOTS Strategy’.13 
 
4.2.3 THE REVISED NATIONAL TUBERCULOSIS CONTROL PROGRAMME 
(RNTCP)  
In the light of the recommendations and concerns expressed by the Central 
Health Council, steps were taken since 1993 to implement the Revised National 
Tuberculosis Control Programme (RNTCP) in selected areas with World Bank 
assistance25 
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The RNTCP strengthens the existing NTP infrastructure by creating a sub-
district-level supervisory team (known as the TB Unit), consisting of a treatment 
supervisor (Senior Treatment Supervisor, STS) and a laboratory supervisor 
(Senior TB Laboratory Supervisor, STLS). These are new posts. In addition, a 
medical officer from the general health system serves as Medical Officer—TB 
Control at sub-district level who is specifically allocated tuberculosis control 
duties in addition to his/her other duties.  
 
These 3 individuals constitute the management unit, which is responsible for 
overseeing operations in approximately a 5 lakh population including, on 
average, 5 designated microscopy centres. At each microscopy centre, a state-
of-the art binocular microscope, good quality reagents and new recording and 
reporting proformae are available. More importantly, intensive modular training, 
supervision, and cross-checking of the work of the laboratory technician ensure 
that reliable results are obtained.25 
 
Starting in October 1993, the RNTCP was implemented in a population of 2.35 
million in 5 sites in different states (Delhi, Kerala, West Bengal, Maharashtra, and 
Gujarat). The programme was expanded to a population of 13.85 million in 1995 
and 20 million in 1996. RNTCP thereafter expanded rapidly to cover 30% of the 
population by 2000, 50% of the population by end 2002 and 87% of the 
population (approximately 947 million people) as of end 2004. This is spread 
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across 547 districts of the 31 states and Union Territories (UTs) in India, with 26 
states and UTs being fully covered.  
 
Population coverage by RNTCP in March 2005 has gone up to 1001 million (1 
billion) 90% coverage. It was targeted to cover the entire country by the end of 
200526. 
 
BASIC PRINCIPLES OF THE RNTCP – DOTS STRATEGY 
The basic principles of the RNTCP are27 
1. Political commitment to ensure adequate funds, staff, and other key inputs.  
2. Diagnosis primarily by microscopic examination of the sputum of patients 
presenting to health facilities. 
3. Regular and uninterrupted supply of anti-TB medications including the use of a 
patient-wise box which contains the entire course of treatment for an individual 
patient so that no patient should ever stop treatment for lack of medicines. 
4. Direct observation of every dose of treatment in the intensive phase and at 
least the first dose in the continuation phase of treatment,  
5. Systematic monitoring, supervision and cohort analysis. 
One Senior Treatment Supervisor (STS) for organization of uninterrupted 
treatment and one Senior Tuberculosis Laboratory Supervisor (STLS) for 
ensuring quality laboratory service for every 5 lakh population. Additional staff 
are provided for difficult hilly, tribal, and some urban areas.  
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If 3 AFB smears are negative and there is no response to 1-2 weeks of 
antibiotics, X-ray is taken, and, if consistent with TB, the patient is treated for 
smear-negative TB. If only one of three specimens is positive, an x-ray is taken 
and the patient is evaluated. All treatment is given thrice weekly on alternate 
days. During the intensive phase, every dose is directly observed; medications 
for the continuation phase are packaged into a weekly blister pack, at least the 
first dose of which is directly observed.  
 
Policy direction, supervision, drugs and microscopes are provided by the Central 
Government. Districts receive funds directly from the Central Government out of 
the World Bank or Danida assistance22. Multi-purpose workers are responsible 
for treatment observation. In areas where they are not available, treatment 
observation is done by community volunteers including Anganwadi workers, 
traditional dais, and community and religious leaders. Observation by a family 
member is not acceptable in the programme26. For the success of the 
Tuberculosis treatment the DOTS providers must be organized in patient’s 
convenience rather than the convenience of the treatment service providers. 
 
The goal of RNTCP is to cure at least 85% of new smear-positive cases of 
tuberculosis and to detect at least 70% of such patients, after the desired cure 
rate has been achieved. Clearly, both good outcomes and high case detection 
rates are essential. Curing the patients reliably results in a “recruitment effect” – 
wherever effective services are offered, case detection rates steadily increase. 
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Cured patients act as one of the best motivators promoting case detection and 
patient adherence to treatment. 
 
Perhaps the greatest strength of the RNTCP is the new recording and reporting 
system. This system ensures accountability for each and every patient started on 
treatment. RNTCP shifts the responsibility for cure from the patient to the health 
system 
 
The “Stop TB” Department in the World Health Organization has developed a 
strategy called “Public–Private Mix DOTS” (PPM-DOTS). The strategy consists 
of DOTS implementation in the private sector according to WHO guidelines, 
provision of free drugs and some financial support by the government, 
strengthened collaboration between public and private providers through 
improved referral and information systems, contracts between the public and 
private sectors, and continuous dialogue.PPM-DOTS can be an effective, 
affordable and cost-effective approach to improving TB control in India28 
The costs of the programme have been consistently low, with lower-than- 
expected unit cost of drugs and microscopes. A full course of anti-TB drugs costs 
less than US$ 7 per patient. The total programme expenditure has been 
approximately US$ 0.05 per person covered per year.29  
 
 
 
 
 23
4.3 PROBLEMS WITH TB CONTROL --   Continuing challenges 
     
Despite having a definitive cure and its pathogenesis well understood, 
tuberculosis remains a major unsolved health problem of worldwide dimensions. 
Why has this happened? Anti-tuberculosis treatments (ATT) are comparatively 
long, and even with present day short course chemotherapy, six months of 
regular drug intake is mandatory. Almost without exception, experts acknowledge 
the role of patient compliance to treatment as one of the major contributing 
factors to this dilemma.30 It may be, as Addington put it, “The most serious 
remaining problem in the control of tuberculosis…is non adherence”.31  
 
4.3.1 Multidrug-resistant TB (MDR-TB) is a form of TB that does not respond to 
the standard drug treatment. MDR-TB is present in virtually all 109 countries 
recently surveyed by WHO and partners. 
450 000 new MDR-TB cases are estimated to occur every year. The highest 
rates of MDR-TB are in countries of the former Soviet Union and China. 
Projects managing MDR-TB can apply through the Green Light Committee for 
access to quality assured MDR-TB drugs at reduced prices – in some cases by 
more than 90%.The Committee is operated by WHO and the StopTB partnership.  
NTI, Bangalore conducted drug resistance surveillance (DRS) in the four districts 
of Mysore (2001), Hoogly (2003), Mayurbhanj (2003) and also in Bangalore city 
(1999) where MDR-TB levels amongst patients with no history of previous 
treatment were observed to be 1.2 percent, 3.0 percent, 0.7 percent, and 2.2 
percent, respectively (NTI 2003)10,11,12. The above data can be considered to 
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represent a fairly accurate picture of true primary resistance. the multi-drug 
resistance in previously treated cases was found to be 12.8 percent and ranged 
from 8.4 to 17.2 percent.32 
4.3.2 TB and HIV/AIDS a lethal combination, each speeding the other's 
progress. Because HIV weakens the immune system, someone who is HIV/TB 
co-infected is many times more likely to become sick with TB than someone 
infected with TB who is HIV-negative. TB is a leading cause of death among 
people who are HIV-positive, accounting for approximately 13% of AIDS-related 
deaths worldwide. In Africa, HIV is the single most important factor determining 
the increased incidence of TB over the past 10 years. In 2004, out of an 
estimated 8.9 million new TB cases worldwide, 3.9 million were diagnosed by 
laboratory testing and 741,000 also were HIV-positive.  An estimated 1.7 million 
people died of TB in 2004, 15% of whom were coinfected with HIV.TB accounts 
for up to a third of AIDS deaths worldwide.  
Improved collaboration between TB and HIV/AIDS programmes will lead to more 
effective control of TB among HIV-infected people and to significant public health 
gains.HIV-positive people can easily be screened for TB; if they are infected they 
can be given prophylactic treatment to prevent development of the disease or 
curative drugs if they already have the disease. TB patients can be offered an 
HIV test; indeed, research shows that TB patients are more likely to accept HIV 
testing than the general population. This means TB programmes can make a 
major contribution to identifying eligible candidates for ARV treatment. 
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4.3.3 RELAPSE IN TUBERCULOSIS 
 
Relapse is defined as “a patient previously treated for tuberculosis who has been 
declared cured or treatment completed, and is diagnosed with bacteriologically 
positive (smear or culture) tuberculosis”.33 The goal of tuberculosis treatment is 
to ensure relapse-free cure while preventing the emergence of drug resistance. 
Use of a four-drug regimen in DOTS strategy reduces the risk both of drug 
resistance developing and of failures and relapses. If a patient defaults on 
treatment after the initial intensive phase, relapse is less likely34. 
 In a longitudinal survey and analytical studies, it was found that relapse still 
accounted for about 15–20% of the annual incidence of newly registered 
infectious cases. Controlled clinical trials in which patients were followed up 
regularly for 2 years or more have shown that the frequency of relapse is around 
3–7% with standardized short-course chemotherapy. The relapse rates in 
randomized-controlled trials of SCC done in India showed a relapse rate of 5.8% 
to 15.3% (Appendix IV).  More than 80% of relapses occur with organisms 
susceptible to the tuberculosis drugs used earlier.35 
 
The individual risk of relapse among persons with a history of bacteriologically 
confirmed tuberculosis varied substantially and was determined mainly by the 
factors whether or not the regimen given was adequate and regularly taken; and 
the time that had elapsed since smear / culture conversion to negative was 
achieved. Approximately 80% of the relapses occur within 6 months of stopping 
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treatment.33The WHO recommended DOT has the positive influence on bringing 
down the relapse.  
4.3.4 Treatment failure is defined as continued or recurrently positive smears 
during the course of antituberculosis therapy. After 3 months of multidrug therapy 
for pulmonary tuberculosis caused by drug-susceptible organisms, 90--95% of 
patients will have negative smears and show clinical improvement. Thus, patients 
with positive smears after 3 months of what should be effective treatment must 
be evaluated carefully to identify the cause of the delayed conversion. Patients 
whose sputum smears remain positive after 4 months of treatment should be 
deemed treatment failures.  
The main reasons for failure are premature cessation of treatment (default) and 
irregularity in taking drugs, prescription of inadequate regimens, drug resistance, 
delay in starting treatment, drug toxicity, malabsorption of drugs, laboratory error, 
and extreme biological variation in response. If treatment failure occurs, early 
consultation with a specialty center is strongly advised. If failure is likely due to 
drug resistance and the patient is not seriously ill, an empirical retreatment 
regimen could be started or administration of an altered regimen could be 
deferred until results of drug susceptibility testing from a recent isolate are 
available. If the patient is seriously ill or sputum AFB smears are positive, an 
empirical regimen should be started immediately and continued until 
susceptibility tests are available. For patients who have treatment failure, M. 
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tuberculosis isolates should be sent promptly to a reference laboratory for drug 
susceptibility testing to both first- and second-line agents.  
 
 
4.3.5 Defaulting Treatment and Side-effects: Obstacles to Managing 
Patients? 
 
The failure to take medications as prescribed is a universal and perplexing 
phenomenon that must always be taken into consideration in any efforts to treat 
patients or control disease in a community. Adherence to treatment is one of the 
biggest challenges facing both TB patients and the TBcontrol programmes. 
"DOTS treatment is intensive and requires on-going commitment and 
responsibility of each patient".  It is commonly accepted by many health care 
workers that poor adherence to treatment is mainly a problem arising from 
misconceptions of the patient about the disease and its treatment. Health 
education is therefore usually seen as the most powerful tool to overcome 
defaulting in treatment. However, human behaviour is complex and there is no 
single psychosocial construct for health behaviour that is reliable and accurate in 
predicting treatment adherence, including TB. 
The expense of treatment, in terms of both time and money, is a further 
deterrent to patient compliance. Complicated regimens are associated with even 
higher default rates. An operational research project conducted between 1996 
and 1998 to assess the needs and perspectives of patients and providers in two 
chest clinics in Delhi, Moti Nagar and Nehru Nagar, during the introduction of the 
new strategy concludes that the reasons for default stem from a poor correlation 
between patient and programme needs and priorities, and from particular 
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characteristics of the disease and its treatment. Patient needs that were not met 
by the health system included convenient clinic timings, arrangements for the 
provision for treatment in the event of a family emergency and provision for 
complicated cases like alcoholics. The problems facing the provider were poor 
interpersonal communication with the health staff, lack of attention and support at 
the clinic, difficulty for patients to re-enter the system if they missed treatment 
and, in certain areas, long distances to the clinic. Problems related to diseases 
were inability of the staff to deal with drug side-effects, and patients’ conception 
of equating well-being with cure. Simple, practical measures could improve the 
provision of tuberculosis (TB) treatment: more flexible hours, allowances for poor 
patients to reach the clinics and training health care staff for respectful 
communication and monitoring drug side-effects. The findings indicate a need to 
rethink the label of ‘defaulter’ often given to the patients. The important areas for 
future operational research is also highlighted. 36 
Thus, the key to treatment success is to be found in the organization of the 
delivery and adequate administration of treatment. Even the best available 
regimen will have a low success rate if treatment services are not focused on 
facilitating patient access to care and ensuring regular drug intake. 
 
 
 
 29
4.3.6 Extrapulmonary Tuberculosis  
Tuberculosis can involve virtually any organ or tissue in the body. Nonpulmonary 
sites tend to be more common among children and persons with impaired 
immunity. EPTB cases form a significant proportion (8-14 percent) of the 
RNTCP’s new case load. 
 RNTCP classification of extrapulmonary TB: 
Seriously ill TB meningitis, Disseminated TB, TB pericarditis, TB peritonitis & 
intestinal TB, Bilateral or extensive pleurisy,Spinal TB with neurological 
Complications, Genito-urinary tract 
Not seriously ill_ Lymph node TB Pleural effusion (unilateral) , Bone (excluding 
spine) , Peripheral joint(s) 
To establish the diagnosis of extrapulmonary tuberculosis, appropriate 
specimens including pleural fluid; pericardial or peritoneal fluid; pleural, 
pericardial, and peritoneal biopsy specimens; lymph node tissue; and bone 
marrow, bone, blood, urine, brain, or cerebrospinal fluid should be obtained for 
AFB staining, mycobacterial culture, and drug susceptibility testing (1). Tissue 
specimens should also be examined microscopically, after routine and AFB 
staining, but the absence of AFB and of granulomas or even failure to culture M. 
tuberculosis does not exclude the diagnosis of tuberculosis. Bacteriological 
evaluation of the response to treatment in extrapulmonary tuberculosis is often 
limited by the difficulty in obtaining follow-up specimens. Thus, response often 
must be judged on the basis of clinical and radiographic findings. In developing 
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countries, the lack of diagnostic resources adds to the problems.This often leads 
to empirical treatment based on clinical grounds without pathological and/or 
bacteriological confirmation, leading to over-diagnosis and unnecessary  
treatment. This was shown in a study at TRC, Chennai, where only 34 percent of 
373 biopsies done on clinically diagnosed cases of LNTB, had histopathological 
confirmation37. 
 
 
 FEW STUDIES ON CAT II ATT: 
 
i) RE-TREATMENT OUTCOME OF SMEAR POSITIVE 
TUBERCULOSIS CASES UNDER DOTS IN BANGALORE CITY 
 
1) A cohort of 226 smear and culture positive re-treatment cases, initiated on Cat 
II regimen under DOTS, was followed up prospectively from April 1999 to 
September 2001, in Bangalore to study the treatment outcome along with the 
drug susceptibility status. The overall favourable re-treatment outcome in the 
cohort was only 39.8% as a result of a high proportion of ‘defaults’ (43.8%). 
However, favourable outcome among those completing the prescribed duration 
of treatment was 75%, MDR –TB among the cohort was 12.8%.8  
 
2) As presented by Dr. Fraser Wares – WHO India ‘RNTCP CAT II regimen in 
retreatment cases’ at the research dissemination workshop Chennai, Jan 2005, 
of the cases from 1997 – 2003 India with a sample size of 2,57,442, a cure rate 
of 67.2% and default rate of 15.2% were noted. 38 
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3) In yet another study carried to evaluate outcome of  DOTS treatment by 
S.L.Chadha and R-P.Bhagi  1999-2000 at municipal corporation of Delhi, cure 
rate of 73.3% and  default rate of 16% with 104 cat II treatment  patients was 
published39 
 4)Vishal Verma, et al Dept. of Tuberculosis & Respiratory Diseases, Amritsar, 
India undertook a study to determine the treatment outcome of DOTS as 
prescribed under RNTCP in 2003. Side effects and radiological 
improvement was also noted. 150 cases of tuberculosis were followed.  
Cure rate was 91% & 71.40% for category I & II. Treatment 
completion rate was 100% for category III. Overall default rate was 
5.33%. Failure rate was 0.67%.40 
 32
THE FUTURE IN TUBERCULOSIS CONTROL --- 
The Stop TB Strategy was launched by W H O in January 2006.40,41 
Vision - A WORLD FREE OF TB 
Goal - To dramatically reduce the global burden of TB by 2015 in line with the 
Millennium Development Goals and the Stop TB Partnership targets  
Objectives 
Achieve universal access to high-quality diagnosis and patient-centred treatment 
Reduce the human suffering and socioeconomic burden associated with TB 
Protect poor and vulnerable populations from TB, TB/HIV and MDR- TB 
Support development of new tools and enable their timely and effective use 
 
Targets 
MDG 6, Target 8: ...halted by 2015 and begun to reverse the incidence.....  
Targets linked to the MDGs and endorsed by the Stop TB Partnership: 
– by 2005: detect at least 70% of new sputum smear-positive TB cases and cure 
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at least 85% of these cases 
– by 2015: reduce prevalence of and death due to TB by 50% relative to 1990 
– by 2050: eliminate TB as a public health problem (<1 case per million 
population)  
Save an additional 14 million lives 
Treat 50 million people for TB43 
Put 3 million TB patients coinfected with HIV onto antiretrovirals 
Treat 800 000 people for MDR-TB 
Produce the first new anti-TB drug in 40 years by 2010 
Develop a new vaccine by 2015 
COMPONENTS OF THE STOP TB STRATEGY 
1. Pursue high-quality DOTS expansion and enhancement 
a. Political commitment with increased and sustained financing  
b. Case detection through quality-assured bacteriology  
c. Standardized treatment with supervision and patient support  
d. An effective drug supply and management system  
e. Monitoring and evaluation system, and impact measurement  
2. Address TB/HIV, MDR-TB and other challenges 
• Implement collaborative TB/HIV activities  
• Prevent and control multidrug-resistant TB  
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• Address prisoners, refugees and other high-risk groups and special 
situations  
3. Contribute to health system strengthening 
• Actively participate in efforts to improve system-wide policy, human 
resources, financing, management, service delivery, and information 
systems  
• Share innovations that strengthen systems, including the Practical 
Approach to Lung Health (PAL)  
• Adapt innovations from other fields  
4. Engage all care providers 
• Public-Public, and Public-Private Mix (PPM) approaches  
• International Standards for Tuberculosis Care (ISTC)  
5. Empower people with TB, and communities 
• Advocacy, communication and social mobilization  
• Community participation in TB care  
• Patients' Charter for Tuberculosis Care  
6. Enable and promote research 
• Programme-based operational research  
• Research to develop new diagnostics, drugs and vaccines  
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.  Provide rapid and inexpensive diagnostic tests at the point of care 
 
Full funding of the Global Plan to Stop TB 2006– 2015 over the next 10 years 
will cost US$ 56 billion, and represents a three-fold increase in investment. The 
estimated funding gap is US$ 31 billion must be bridged. This is equivalent to just 
US$ 2 a year from every person in the industrialized world. 
 
WHO Director-General Dr LEE Jong-wook said: “There is clear evidence that 
investment in TB control works. Even in low-income countries with enormous 
financial constraints, programmes are operating effectively and producing results. 
This same commitment needs to be replicated in African countries and other 
areas where funding and priority for TB control remains fragile.44 
 
 
 
 
 
 
 
 
 36
5. METHODOLOGY 
STUDY DESIGN: Non-concurrent cohort study. Patients followed up 
retrospectively from standard RNTCP treatment cards, belonging to Category II 
Antitubercular treatment in a population covered by C M C H DOTS clinic. 
 
Patients and Methods 
All the Patients started on CAT II ATT  registered under DOTS in CHAD/CMC 
from January 2001 to December 2004 were  considered for the study. 
Information regarding the indication of treatment, the Sputum conversion rates 
and the outcome of treatment at the end of one year such as Cure, default, 
death, completion rate, and failure were analyzed in detail.  
 
All Patients from geographically accessible areas (including Kaniyambadi block 
and Ussoor, Poigai, Pallikonda PHC areas) were followed up in their homes to 
know the present condition,  interviewed using a pretested questionnaire and  2 
sputum samples were collected from all symptomatic patients. 
The relapse rates were estimated based on followup sputum AFBs and cultures. 
Risk factors associated with poor outcomes viz death, default, relapse and failure 
analyzed by patient/ patient relative’s  interviews.  
  
Inclusion Criteria: Patients started on CAT II ATT  between JAN 2001 – DEC 
2004 under RNTCP DOTS regime in CHAD/CMC DOTS clinic. 
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Exclusion Criteria:  Children<15 years (paediatric DOTS). 
Outcome Measures: 
Default rate 
Treatment completion rate 
Cure rate 
Treatment failure rate 
Relapse rate over time of follow up 
Sputum AFB and sputum Culture status of the patients who are symptomatic 
during the follow up.  
Risk factors leading to poor outcomes – default, failure and relapse. 
. 
Definition of terms: Type of Case6 
 
Relapse—A patient declared cured of Tuberculosis by a physician but who 
reports back to the health service and is found to be bacteriologically positive. 
Failure—Smear positive patient who remains smear positive at 5 months or 
more after starting treatment.  It also includes a patient who was initially smear 
negative but becomes smear positive during treatment. 
Treatment after Default—A patient who received antituberculosis treatment              
for one month or more and returns to treatment after having defaulted, i.e. not 
taken anti-tb drugs consecutively for 2 months or more. 
Other -  Patients who do not fit into the above mentioned categories. Reasons 
for putting a patient in this category must be specified. 
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Definitions: treatment outcomes6  
Cured -Initially smear+ve patient who has completed treatment and had negative 
sputum smears, on at least two occasions, one of which was at completion of 
treatment. 
Treatment completed -Sputum smear+ve case who has completed treatment, 
with negative smears at the end of the initial phase but none at the end of 
treatment Or: Sputum smear-ve patient Or: Extra-pulmonary patient who has 
received a full course of treatment and has not become smear+ve during or at 
the end of treatment. 
Success - The sum total of patients ‘Cured’ and ‘Completed’ treatment. 
Died - Patient who died during treatment, regardless of cause 
Failure - Any TB patient who is smear+ve at ≥5 months after starting treatment. 
Failure also includes a patient who was treated with Category III regimen but who 
becomes smear+ve during treatment. 
Defaulted - A patient who, at any time after registration, has not taken 
anti-TB drugs for 2 months or more consecutively. 
Relapse - A patient declared cured of Tuberculosis and bacteriologicaly negative 
at completion of treatment but who reports back to the health service and is 
found to be bacteriologically positive on followup. 
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  Sample size:  
                        4pq/d2 
                       p= prevalence (assuming 50% success rate of Cat II on followup) 
                       q= 1-p 
                       d= 20% relative precision 
                       Sample Size= 4(.5*.5) / (0.1)2 = 100 
 
                      Assuming 10% loss to follow-up, sample size of 110 
 
 
Data entry and statistical analysis was done using Epi Info version 3.2.2 from 
CDC, Atlanta and SPSS data analysis package version 12.0. Comparison of 
treatment success, death, relapse rates and risk factors for poor outcomes was 
done using appropriate statistical tests.  
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6. RESULTS 
 
ANALYSIS OF ALL PATIENTS WHO HAD CAT II ATT FROM 2001 TO 2004 
FROM CHAD/CMCH DOTS CLINICS. 
6.1  BASELINE CHARACTERISTICS 
Table 6.1.1 YEAR WISE BREAK UP OFALL PATIENTS TREATED UNDER 
RNTCP FROM CMCH FROM 2001 TO 2004 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
Table 6.1.2 INDICATION FOR CAT II TREATMENT 
 
 
 
 NUMBERS PERCENTAGE 
RELAPSE 197 63.8 
DEFAULT 61 19.7 
FAILURE 29 9.4 
OTHERS 21 6.8 
TRANSFER IN 1 0.3 
TOTAL 309  
YEAR TOTAL PATIENTS CAT II 
2001 448 82 (18.3%) 
2002 645 97(15.3%) 
2003 623 65(10.4%) 
2004 629 65(10.3%) 
TOTAL 2345 309(13.2%) 
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Table 6.1.3.1 AGE DISTRIBUTION OF PATIENTS ON CAT II ATT 
 Frequency Percent 
Cumulative 
Percent 
 <20 15 4.9 4.9 
  21-30 73 23.9 28.8 
  31-40 75 24.3 53.1 
  41-50 72 23.3 76.4 
  51-60 52 16.8 93.2 
  61-70 18 5.8 99.0 
  >70 3 1 100.0 
  Total 309 100.0   
 
 
 
 
 
 
 
 
GRAPH 6.1. AGE DISTRIBUTION OF ALL CASES. 
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TABLE6.1.3.2 AGE AND SEX DISTRIBUTION OF ALL CAT II CASES 
 
AGE GROUPS MALES FEMALES 
 <20 6 (2.4%) 9(15.8%)
  21-30 50(19.8%) 23(40.3%)
  31-40 64(25.4%) 12(21.1%)
  41-50 64(25.4%) 8(14%)
  51-60 48(19%) 4(7%)
  61-70 17(6.7%) 1(1.8%)
  >70 3(1.2%) 0
  Total 252 57
 
 
 
 
 
 
 
GRAPH 6.1.3.2 AGE AND SEX DISTRIBUTION OF ALL CAT II CASES 
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Table 6.1.4     TYPE OF CASE 
 
CASES Frequency Percent 
EXTRA PULMONARY 13 4.2 
PULMONARY 296 95.8 
Total 309 100.0 
 
 
 
 
 
 
 
 
Table 6.1.5 SPUTUM STATUS AT INITIATION OF TREATMENT. 
 
 NUMBERS PERCENTAGE 
1+ 131 42.4 
2+ 71 23.0 
3+ 81 26.2 
NEG 9 2.9 
NOT AVAILABLE 11 3.5 
SCANTY 5 1.5 
NUMEROUS 1 0.3 
 
TOTAL 
 
                            309 
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Table 6.1.6 OUTCOME OF ALL PATIENTS AT THE END OF INITIAL 
TREATMENT 
(N=309) NUMBERS PERCENTAGE 
CURED/COMPLETED 197 63.8 
DEFAULT 46 14.9 
EXPIRED 41 13.3 
FAILURE 19 6.1 
TRANSFERRED OUT 06 1.9 
 
 
 
 
 
 
 
 
Table 6.1.7 INDICATION OF TREATMENT VS OUTCOME OF TREATMENT 
 
 
 
                                                   OUTCOME OF TREATMENT 
 SUCCESS DEFAULT EXPIRED FAILURE TRANSFER TOTAL
DEFAULT 35(57.3%) 14(23%) 9(14.7%) 2(3.3%) 1(1.7%) 61 
FAILURE 17(58.6%) 2(6.9%) 3(10.3%) 7(24.2%) 0 29 
OTHERS 18(85.7%) 1(4.8%) 2(9.5%) 0 0 21 
RELAPSE 127(64.5%) 29(14.7%) 27(13.7%) 10(5.1%) 4(2%) 197 
TRANSFER 
IN 0 0 0 0 1 1 
 
 
 
INDICATION 
OF 
TREATMENT 
TOTAL 197 46 41 19 6 309 
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FOLLOW UP STUDY RESULTS- 6.2 
 
TABLE 6.2.1 NUMBER OF PATIENTS FOLLOWED-UP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 6.2.2 INDICATION FOR TREATMENT IN PATIENTS FOLLOWED-UP 
 
 NUMBER OF PATIENTS PERCENTAGE 
RELAPSE  71 64.5 
DEFAULT 21 19.1 
FAILURE 8 7.3 
OTHERS 10 9.1 
TOTAL 110 100 
 
 
TABLE 6.2.3 INITIAL OUTCOME OF TREATMENT IN PATIENTS FOLLOWED-
UP 
 
 NUMBER OF PATIENTS PERCENTAGE 
TREATMENT SUCCESS 80 72.7 
DEFAULT 25 22.7 
FAILURE 5 4.6 
TOTAL 110 100 
 
 
 
 
 
YEAR TOTAL  CAT II 
PATIENTS 
PATIENTS 
FOLLOWED UP
2001 82  18 
2002 97 36 
2003 65 32 
2004 65 24 
TOTAL 309 110 
 46
TABLE 6.2.4LITERACY STATUS OF PATIENTS FOLLOWED-UP 
 
 NUMBER OF PATIENTS PERCENTAGE 
ILLITERATE 33 30 
READ AND WRITE 68 61.8 
READ ONLY 9 8.2 
TOTAL 110 100 
 
 
TABLE 6.2.5 CAUSES FOR INTERUPTION OF TREATMENT AS TOLD BY 
PATIENTS 
 
SIDE EFFECTS 12 
SEVERELY ILL 3 
OUT OF STATION 27 
FELT BETTER 3 
LACK OF AWARENESS 2 
NOT CONVINCED OF TB 
DIAGNOSIS 2 
NO FAMILY SUPPORT 1 
OTHER CAUSES 5 
 
 
 
TABLE 6.2.6 ORIGIN OF CAT II (H/O CAT I TREATMENT FROM) 
 
 Frequency Percent
Valid 
Percent 
 RNTCP 57 51.8 71.3
  PRIVATE 23 20.9 28.8
  Total 80 72.7 100.0
 NOT 
TRACEABLE 30 27.3  
Total 110 100.0  
NOT TRACEABLE ARE MORE FROM THE DEATH GROUP 
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TABLE 6.2.7 FOLLOW-UP SPUTUM RESULTS 
 
 NUMBER OF PATIENTS 
NEGATIVE 62 
1+ 1 
3+ 1 
NOT AVAILABLE* 46 
TOTAL 110 
 
*SPUTUM NOT AVAILABLE INCLUDES PATIENTS WHO ARE DEAD AND 
ALSO PATIENTS WHO WERE LOST TO FOLLOWUP. 
 
 
 
TABLE 6.2.8 CURRENT STATUS OF PATIENTS FOLLOWED-UP 
 
 NUMBER OF PATIENTS PERCENTAGE 
SUCCESS 64 58.1 
DEATH 35 31.8 
RELAPSE 2 1.8 
LOST TO FOLLOW-UP 5 4.5 
RETREATED 4 3.6 
TOTAL 110 100 
 
 
 
TABLE 6.2.9 INITIAL OUTCOME VS CURRENT STATUS ON FOLLOW-UP 
 
 
CURRENT STATUS 
 SUCCE
-SS 
DIED LOST RELA 
-PSE 
RETR 
EATME
NT 
TOTAL 
SUCCESS 52 21 1 2 4 80 
DEFAULT 10 11 4 -- -- 25 
FAILURE 2 3 -- -- -- 5 
INITIAL 
OUTCO   
 -ME 
TOTAL 64 35 5 2 4 110 
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TABLE 6.2.10  UNIVARIATE ANALYSIS OF FACTORS CONTRIBUTING TO 
THE POOR OUTCOMES IN THE PATIENTS FOLLOWED UP 
 
 POOR 
OUTCOME 
(N=46) 
GOOD 
OUTCOME
(N=64) 
RELATIVE 
RISK 
95% C.I      P-
VALUE 
MALE 42 51 1.92 0.79-4.65 0.09 
MEALS<2/DAY 24 17 1.84 1.19-2.82 0.006* 
SMOKING 30 27 1.74 1.08-2.81 0.017* 
ALCOHOLIC 27 25 1.59 1.01-2.49 0.041* 
DIABETES 7 5 1.47 0.086-2.51 0.21 
EDUCATION </=5STD 32 31 1.71 1.03-2.82 0.027* 
DEFAULT 15 10 1.65 1.07-2.52 0.036* 
INTERUPTION OF RX 28 30 1.39 0.88-2.21 0.147 
HIV INFECTION 5 1 2.17 1.41-3.34 0.029# 
POOR HOUSING 31 20 2.39 1.47-3.90 0.0001* 
FAMILY H/O TB 9 7 1.43 0.87-2.36 0.205 
 
 
 
* = SIGNIFICANT 
 
# FISHER P=0.04  SIGNIFICANT 
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TABLE 6.2.11 
 MULTIVARIATE ANALYSIS OF RISK FACTORS FOR POOR OUTCOMES  
  
  B S.E. Sig. Exp(B) 95.0% C.I.for EXP(B) 
          Lower Upper 
 HIV 3.463 1.294 .007 31.918 2.529 402.815 
  alcohol .700 .505 .166 2.014 .749 5.419 
  meals 1.064 .488 .029 2.899 1.114 7.546 
  literacy .867 .537 .106 2.379 .831 6.812 
  default .902 .538 .094 2.465 .858 7.082 
  SMOKE .892 .516 .084 2.441 .888 6.709 
  housing .864 .504 .086 2.373 .884 6.371 
  Constant -2.916 .628 .000 .054     
 
a  Variable(s) entered on step 1: HIV, alcohol1, meals, lit, default, SMOKE, hou. 
 
 
 
TABLE 6.2.12 
 
DURATION OF FOLLOW UP- IN PERSON YEARS 
 
YEAR PERSONYEARS 
 
POOR OUTCOMES 
2001 52.25 10 
2002 90.58 17 
2003 70.25 11 
2004 28 8 
 
 
 
 
TOTAL DURATION OF FOLLOW UP = 241 PERSON YEARS 
 
 
CUMULATIVE DEATH RATE  = 141.03 per 1000 persons years.   
 
 
CUMULATIVE RELAPSE RATE = 24.88 per 1000 persons years follow up. 
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GRAPH 6.3   SURVIVAL ANALYSIS DEPENDING ON OUTCOME OF CAT II 
TREATMENT  USING KAPLAN-MEIER SURVIVAL ANALYSIS FUNCTION 
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Table 6.2.13 CAUSE OF DEATH AMONG THOSE FOLLOWED UP. 
 
CAUSE OF DEATH Total 
ALCOHOLIC LIVER DISEASE 1 
CHRONIC RENAL FAILURE 1 
CA-OESOPHAGUS 1 
HIV/AIDS 3 
MYOCARDIAL INFARCTION 2 
PNEUMONIA 1 
ACCIDENTAL 1 
TB  
(NO OTHER ATTRIBUTABLE CAUSE)
26 
Total 36 
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7. DISCUSSION 
 
 
Many interventions have evolved for better control of tuberculosis over the last 
few decades.45  Of these, many are aimed at making the treatment of 
tuberculosis simpler while maintaining effectiveness. The current WHO DOTS 
strategy brings as a package, all the essential elements required for effective 
tuberculosis control. Many National Tuberculosis Programs have adopted the 
DOTS strategy and showed consistently higher cure and completion rates.46 
 
The analysis proceeds in two steps. First, study of patient profile and primary 
outcome and second on evaluation of current status.  
Primary outcome refers to the outcome of at the end of treatment as defined by 
WHO DOTS strategy criteria. Current status has been divided into Sputum 
negative, Relapsed, Lost to follow up and Expired at follow up. 
For evaluation of the primary outcome and patient profile, data from all 309 cases 
of patients who underwent CAT II antituberculosis  treatment from CHAD/ CMC 
DOTS clinics between 2001 and 2004, analysed from the tuberculosis database 
and treatment cards.  
This is then followed by analysis of the current status of the patients who were 
followed up by house visits from a defined geographical area comprised 110 
patients out of 309 as per the sample size. Relapse rates and mortality are 
calculated using this data.  
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7.1 BASELINE CHARACTERISTCS (Refer Tables 6.1.1 & 6.1. 2) 
Total number of 2345 patients had been started on DOTS from CHAD/CMC 
DOTS clinics from 2001 to 2004.  Out of this category II treatment cases were 
309 in total (13.2%). 
 
Year wise break(table-6.1.1) up showed gradual decrease in percentage of 
Category II cases, which indirectly shows the efficiency of DOTS programme. 
 
AGE AND SEX DISTRIBUTION OF PATIENTS ON CAT II ATT  
(TABLE-6.1.3,6.1.4) AND GRAPHS (6.1.3.1,6.1.3.2) 
 
Age distribution of patients showed the typical peaking in the productive age 
group (20 – 50 years) about 71.5% of the total cases. 
Tuberculosis hinders the socioeconomic development of the country. 75% of 
people with tuberculosis are in the economically productive age group of 15–54 
years as -quoted by different writers. Besides the disease burden, TB also 
causes an enormous socio-economic burden on India.3 
Age and Sex distribution data showed more number of cases in females seen in 
lower age groups as compared to males. Not to forget  less number of female 
patients . 
 
Indication for Category II treatment showed 63.8% were due to relapse and 
19.7% were due to default during earlier treatment. The duration between 
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completion of Cat I treatment to relapse ranged between 6 months to several 
years which triggered more interest in the investigation of relapse rates. 
 
7.2 ANALYSIS OF PRIMARY OUTCOMES (Refer Tables 6.1. & 6.1.) 
These outcomes are obtained from the data using the treatment cards of 309 
 Category II patients. Outcomes are categorized according to the WHO 
definitions6 
Considering both cured and completed as treatment success -63.8%had 
successful outcome. 
Cure rates in sputum positive patients was 61.94% is within the range of other 
studies where in Bangalore cohort  had a cure rate of 39.8%.8 vs Delhi study 
which had a better cure rates 73.3% .39 
Default rate was 14.9% was less in comparison to other studies. Delhi study had 
a default rate of 16% against Bangalore cohort which had a high defaults of 
43.8% where as overall default rate in India over 6 years as quoted by Dr. Fraser 
Wares – WHO India was 15.2%.38 
Failure rate of 6.1% has to be followed further to rule out MDR TB.  
Death rate was 13.3% during treatment might be due to severity of illness in 
people who come to Category II treatment. 
Treatment success rates in patients who completed treatment as prescribed was 
91.2% which is very encouraging. 
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Sputum status at initiation of treatment shows gradual decrease in highly infected 
cases over years. 
 
Cross table on indication of treatment vs outcome shows better success rate 
among relapse patients compared to other indications.  
 
Chances of Default patients going in to default again during treatment (23%) is 
statistically significant as compared to other indications.(RR1.78(1.01-3.12),  
Chi sq -3.9 and p=0.048) 
 
Cat. II failure among patients with Cat. I failure was 24.2% which might indicate       
MDR TB.  47 
 
7.2 ANALYSIS OF THE CURRENT STATUS OF THE PATIENTS 
INTERVIEWED (Refer Section 6.2) 
 As per the sample size calculated 110 patients from a defined 
geographical area were followed up to their homes. (APPENDIX I)    
           
7.2.2 OUTCOME OF THE INITIAL TREATMENT OF THE PATIENTS FOLLOWED UP (Refer 
Table 6.2.2) 
Depending upon the primary outcome of treatment from the standard treatment 
cards , 80 people with treatment success , 25 default patients and  5 failure 
patients were visited from the  accessible areas. Year-wise break up and 
indication for treatment has been given in table 6.2.1 and 6.2.2. 
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On follow up, it was found that majority of cases(71.2%)  had been earlier treated 
with Cat I under RNTCP. Details regarding history of  evolution of cat II could not 
be found in 30 cases esp in the death group. (TABLE 6.2.6) 
 
Total duration of 241 person years were followed up. 
 
Death, relapse and lost to follow up were considered as poor outcomes. 
 
On follow up 58.1% were well.  31.8% had died during the period between 
completion of the treatment and follow up.  Only two cases of relapse were found 
during the study.  4.5% of cases were lost to follow up due to migration or other 
causes.  Four people (3.6%) who had already been retreated and cured were 
considered as relapsed. 
 
Of the people with successful Cat.II treatment 62.1% had a good outcome on 
follow up as compared to 39% with defaults.  There was no major statistical 
difference  in follow up outcome between the sexes. 
 
 Cumulative death rate was 141.03 per 1000 persons years.  Calculated by  
dividing total deaths by duration of follow up.  
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 Relapse rates was 24.88 per 1000 persons years follow up.  Only 2 
sputums were found to be positive during follow up.  Cases who had relapsed 
and retreated before follow up were also included in calculating relapse rates.   
 
 
Survival analysis showed statistically significant difference among the different 
groups based on the Cat.II treatment outcomes.  People who completed 
treatment as per the prescribed treatment have better survival compared to 
people who defaulted or treatment failures (Log Rank  of 8.70 and significance of 
.0032). 
 
RISK FACTORS FOR POOR OUTCOMES 
 Different attributes like diabetes, history of smoking, consumption of 
alcohol, HIV infection, male sex, housing, number of meals per day, history of 
default or interruption of treatment were considered as quoted by previous 
studies.  In various reviews poor outcomes have been shown to have 
inconsistent relationship with demographic characteristics such as age, gender, 
marital status, alcoholism and others.48 
 
 
 Univariate analysis (Table 6.12)  showed the significance relationship 
between HIV infection, education less than 5th standard, history of default, history 
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of smoking and alcohol consumption and meals less than two/day with poor 
outcomes.  
 
 Multivariate analysis showed only HIV co-infection and less than two 
meals per day as a significant risk factors for poor outcome when other risk 
factors were adjusted.(TABLE-6.13) 
 
 
REASONS FOR INTERUPTION OF TREATMENT AS GIVEN BY PATIENTS  
 
There were various reasons given by the patients for their defaulting on 
treatment. Severe illness and co-morbid conditions such as renal failure played 
an important in a few cases. Going out of station for work or due to monetary 
problems were other cited problems. Side effects of drugs and feeling better 
subjectively were other reasons. These are similar to the reasons given in other 
studies.16, 17 About half of these defaults are probably preventable if the program 
can adapt itself to patient needs and problems. For example, education about the 
drugs side effects and transfer of patient-wise drug boxes to areas more 
accessible to the patient if he goes out of station for a while, can be some of the 
interventions. 
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Sub-study on patients knowledge regarding tuberculosis by  questionnaire 
showed following factors. 
1. Tuberculosis still considered as stigma,12(20%) respondents 
wanted to hide the factor that they had/were treated for T B, 
Reasons quoted were being unmarried, fear of loosing job 
among others. 
2. Twenty two people did not know whether TB can be cured. 
Eight of them thought treatment of TB is life long. 
3. 40 (66%) respondents said TB spreads through cough. 
4. In 97% of patients their family people were supportive during 
illness. 
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7.7 SUMMARY 
 
Tuberculosis remains a major public health problem in India.  
There was a need to look at Cat II patients and their outcomes as very little 
literature was available on this topic. 
This is a non-concurrent cohort study, which studied the category II  
patients(309)  from standard TB treatment records maintained in the CHAD/CMC 
DOTS clinics from 2001 to 2004. A sample of this patients(110) from 
geographically accessible areas were followed up to know the current status and 
find relapse rates over time. 
The data collected was analyzed using adequate statistical tests. 
 
PATIENT PROFILE 
Total number of 309 patients treated with category II ATT from 2001to 2004 were 
considered for the study.  
 
 
o Cure rate of 61.94% among the sputum positive cases. 
o Overall treatment success rate was 63.8%. However, successful 
outcome, among those completing the prescribed duration of 
treatment was 91.2% which is encouraging. 
o Default rates of 14.9% are still high and needs to be tackled to 
improve outcome under programme conditions. 
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o Age distribution shows the typical pattern of TB affecting maximum 
the productive age groups. Cumulative incidence of  93.2% in age 
groups <60years. 
o 13.3% of cases had died during treatment. 
 
FOLLOW UP STUDY 
Total number of 110 cases were followed up at their homes from a defined 
geographical area to find the current status and calculate relapse rates over time. 
Total period of follow up was  241 person years.  
Average of 2.2 years of follow up per case. 
1) Survival statistically better among treatment success patients as 
compared to defaults and failures. 
2) Cumulative relapse rate was found to be 24.88 per 1000 persons 
years follow up. 
3) Significant risk factors for poor out comes in the univariate analysis 
included educational status, housing, status of default, smoking 
habit, alcohol consumption, co-infection with HIV  and inadequate 
food availability/intake. All these factors were statistically 
significant. Diabetes, family history of tuberculosis and male sex 
were found not to be significant. 
4) Multivariate analysis showed HIVco-infection and inadequate food 
to be significant. 
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A cure rate of 61.94% and the success rate of   91.2% among Cases who took 
adequate treatment,  supports the strength of Cat II as a standard re-treatment 
regimen. It suggests that regular the treatment  under direct observation 
response is better. This gain is also visible on followup  by better survival 
chances. 
 
The study also underscores the importance of treatment adherence for achieving  
 
success. 
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8. LIMITATIONS OF THE STUDY 
 
1) IN THE FOLLOW UP STUDY, the risk factors for poor outcomes 
especially deaths,  were secured from the family members which 
may be biased. 
2) True prevalence of HIV infection in this study population is not 
known as not everyone have been screened. 
3) Adequate information could not be collected from few incomplete 
treatment cards . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64
 
 
 
 
 
9. CONCLUSIONS 
 
• Category II treatment under DOTS therapy still works with a success rate 
of 91.2% in patients who take prescribed duration of treatment as contrary 
to the belief that adding a single drug to a failing regimen will not help. 
 
• Inadequate  Food and HIV co-infection play a major role in poor outcomes 
 
• Overall survival is better in treatment success patients.  
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APPENDIX I             PATIENTS SELECTION AND FOLLOW UP FLOW CHART 
 
 
TOTAL 
CAT II  
PT-309 
SUCCESS 
197 (63.8%) 
DEAD 
/LOST 
47(15.2%) 
FAILURE 
19(6.1%) 
DEFAULT 
46(14.9%) 
PATIENTS  FROM ACCESIBLE 
AREAS FOLLOWED UP 
                       110 
SUCCESS    
64 (58.1%) 
DEAD 
35 
(31.8%) 
LOST 
05 
(4.5%) 
RELAPSE 
RETREA
TED -06 
(5.4%) 
IMMEDIATE 
TREATMENT  = > 
OUTCOME 
TOTAL NO. OF TB CASES    
2001-2004 = 2345  
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IMMEDIATE TREATMENT  = > OUTCOME 
 
APPENDIX II 
 
 
LIST OF ABBREVIATIONS 
  
  
AFB Acid Fast Bacillus 
ATT Antituberculosis Treatment 
BCG Bacillus Calmette Guerrin 
BMRC British Medical Research Council 
CDC Centre for Disease Control 
CHAD Community Health and Development 
CMC Christian Medical college 
CP Continuation Phase 
DANIDA Danish International Development Agency 
DFID Danish Fund for International Development 
DOT Directly Observed Treatment 
DOTS Directly Observed Treatment - Short-course 
DTC District Tuberculosis Centre 
IP Intensive Phase 
IUATLD International Union Against Tuberculosis and Lung 
Disease 
MO Medical Officer 
MOTC Medical Officer Tuberculosis Control 
NGO Non-governmental Organisation 
NTP National Tuberculosis Program 
PPM Private-public mix 
RNTCP Revised National Tuberculosis Control Program 
SAT Self Administered Therapy 
SCC Short-course Chemotherapy 
SIDA Swedish International Development Agency 
SPSS Statistical Package for the Social Sciences 
STLS Senior Tuberculosis Laboratory Supervisor 
STS Senior Treatment Supervisor 
TB Tuberculosis 
TRC Tuerculosis Research Centre 
TU Tuberculosis Unit 
WHO World Health Organisation 
PHC Primary Health Centre 
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